Incovacc
- Bharat Biotech’s intranasal vaccine, BBV154 or Incovacc is the world’s first intranasal vaccine to be approved as a booster dose for COVID-19.
- The nasal vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
- As the vaccine is given nasally, it triggers an immune response in the mucosal membrane.
- BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission.
- This is the second heterologous booster to be included in the vaccination programme after ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
News Snippets
- 1 India-Bhutan Hold Talks on Boundary and Cooperation
- 2 New Species of Congrid Eel Discovered
- 3 Delhi Becomes the 28th Legislature to Join NeVA
- 4 U.S. Withdraws from U.N. Climate Damage Fund Board
- 5 India and Vietnam Hold Fourth Policy Planning Dialogue
- 6 US Targets India’s High Tariffs
- 7 India and Armenia Sign MoU on Medical Product Regulation
- 8 Poland & Baltic States to Withdraw from Ottawa Convention
- 9 India and Mongolia Strengthen Strategic Partnership
- 10 New Freshwater Algae Species Discovered in Western Ghats
